Immunoagents

Overexpression of the ErbB2 receptor is associated with the progression of breast cancer, and is a sign of a poor prognosis. Herceptin, a humanized antibody directed to the ErbB2 receptor, has been proven to be effective in the immunotherapy of breast cancer. However, it can result in cardiotoxicity, and a large fraction of breast cancer patients are resistant to Herceptin treat-ment.

13p vinaphone15 28-02-2013 43 3   Download

Immunotherapy, based on mAbs specifically directed against cancer cells, is considered a precious strategy in the fight against cancer because of its selec-tivity and lack of multidrug resistant effects. However, there are obstacles to the complete success of current immunotherapy such as immune responses to nonhuman or even humanized antibodies and the large size of the anti-bodies, which hinders their diffusion into bulky tumors.

9p vinaphone15 27-02-2013 33 2   Download

Two novel human antitumor immunoconjugates, engineered by fusion of a single-chain antibody fragment against human ErbB2 receptor, termed Erbicin, with either a human RNase or the Fc region of a human IgG1 , are selectively cytotoxic for ErbB2-positive cancer cellsin vitro andin vivo.

11p cosis54 05-01-2013 53 5   Download